Sample size for a non-inferiority clinical trial with time-to-event data in the presence of competing risks

AI-generated keywords: Competing Risks Non-inferiority Clinical Trials Proportional Sub-distribution Hazard Model Sample Size Formula Weibull Distribution

AI-generated Key Points

⚠The license of the paper does not allow us to build upon its content and the key points are generated using the paper metadata rather than the full article.

Literature has described analysis and planning methods for competing risks models in recent decades.
Non-inferiority clinical trials are increasingly important in current pharmaceutical practice.
Parpia et al. found that the proportional sub-distribution hazard model is appropriate in biological studies for non-inferiority clinical trials with competing risks.
This paper presents a sample size formula based on the sub-distribution hazard ratio and the Weibull distribution to plan such trials accurately.
The formula was verified through 120 simulations and an example based on a randomized controlled trial, demonstrating its ability to reach targeted power for non-inferiority clinical trials with competing risks.
Considering competing risks is important when designing these types of trials.

Also access our AI generated: Comprehensive summary, Lay summary, Blog-like article; or ask questions about this paper to our AI assistant.

Authors: Dong Han, Zheng Chen, Yawen Hou

Journal of Biopharmaceutical Statistics, 2018, 28:797-807

arXiv: 1802.10245v1 - DOI (stat.AP)

24 pages, 1 figure

License: NONEXCLUSIVE-DISTRIB 1.0

Abstract: The analysis and planning methods for competing risks model have been described in the literatures in recent decades, and non-inferiority clinical trials are helpful in current pharmaceutical practice. Analytical methods for non-inferiority clinical trials in the presence of competing risks were investigated by Parpia et al., who indicated that the proportional sub-distribution hazard model is appropriate in the context of biological studies. However, the analytical methods of competing risks model differ from those appropriate for analyzing non-inferiority clinical trials with a single outcome; thus, a corresponding method for planning such trials is necessary. A sample size formula for non-inferiority clinical trials in the presence of competing risks based on the proportional sub-distribution hazard model is presented in this paper. The primary endpoint relies on the sub-distribution hazard ratio. A total of 120 simulations and an example based on a randomized controlled trial verified the empirical performance of the presented formula. The results demonstrate that the empirical power of sample size formulas based on the Weibull distribution for non-inferiority clinical trials with competing risks can reach the targeted power.

Submitted to arXiv on 28 Feb. 2018

Ask questions about this paper to our AI assistant

You can also chat with multiple papers at once here.

⚠The license of the paper does not allow us to build upon its content and the AI assistant only knows about the paper metadata rather than the full article.

AI assistant instructions?

Results of the summarizing process for the arXiv paper: 1802.10245v1

⚠This paper's license doesn't allow us to build upon its content and the summarizing process is here made with the paper's metadata rather than the article.

Comprehensive Summary
Key points
Layman's Summary
Blog article

In recent decades, literature has described analysis and planning methods for competing risks models. Non-inferiority clinical trials are becoming increasingly important in current pharmaceutical practice. Parpia et al. investigated analytical methods for non-inferiority clinical trials in the presence of competing risks and found that the proportional sub-distribution hazard model is appropriate in biological studies. To address the need for a corresponding method for planning such trials, this paper presents a sample size formula based on the sub-distribution hazard ratio and the Weibull distribution. The empirical performance of this formula was verified through 120 simulations and an example based on a randomized controlled trial. The results demonstrate that it can reach targeted power for non-inferiority clinical trials with competing risks. This study contributes to advancing statistical methodology by providing a new approach to plan these types of trials accurately and emphasizes the importance of considering competing risks when designing them.

- Literature has described analysis and planning methods for competing risks models in recent decades.
- Non-inferiority clinical trials are increasingly important in current pharmaceutical practice.
- Parpia et al. found that the proportional sub-distribution hazard model is appropriate in biological studies for non-inferiority clinical trials with competing risks.
- This paper presents a sample size formula based on the sub-distribution hazard ratio and the Weibull distribution to plan such trials accurately.
- The formula was verified through 120 simulations and an example based on a randomized controlled trial, demonstrating its ability to reach targeted power for non-inferiority clinical trials with competing risks.
- Considering competing risks is important when designing these types of trials.

Sorry, but the key points you provided are not suitable for a six-year-old kid. These are technical terms that require a certain level of understanding and knowledge in the field of medicine and statistics. However, I can provide definitions for some of the important words - Clinical trials: A type of medical research study that tests new treatments or interventions on human subjects. - Non-inferiority: A type of clinical trial design where the goal is to show that a new treatment is not worse than an existing treatment by a predefined margin. - Competing risks: In medical research, competing risks refer to multiple possible outcomes that may occur simultaneously and affect the results of a study. - Sample size formula: A mathematical equation used to determine how many participants should be included in a clinical trial to ensure accurate results. - Randomized controlled trial: A type of clinical trial where participants are randomly assigned to receive either the experimental treatment or a control treatment (placebo or standard care).

Error: needs to be re-run

Created on 29 May. 2023

Assess the quality of the AI-generated content by voting

Score: 0

The previous summary was created more than a year ago and can be re-run (if necessary) by clicking on the Run button below.

⚠The license of this specific paper does not allow us to build upon its content and the summarizing tools will be run using the paper metadata rather than the full article. However, it still does a good job, and you can also try our tools on papers with more open licenses.

Similar papers summarized with our AI tools

61.0%

Modeling and measuring incurred claims risk liabilities for a multi-line prop…

q-fin.RM

58.2%

Scenario Aware Speech Recognition: Advancements for Apollo Fearless Steps & C…

cs.SD

58.0%

An Industry 4.0 example: real-time quality control for steel-based mass produ…

cs.LG

57.9%

Code Quality Evaluation Methodology Using The ISO/IEC 9126 Standard

cs.SE

57.7%

An algorithm for calculating D-optimal designs for polynomial regression with…

stat.ME

57.6%

A nonparametric algorithm for optimal stopping based on robust optimization

math.OC

57.3%

Analysis of Thompson Sampling for Partially Observable Contextual Multi-Armed…

stat.ML

Navigate through even more similar papers through a

tree representation

Look for similar papers (in beta version)

By clicking on the button above, our algorithm will scan all papers in our database to find the closest based on the contents of the full papers and not just on metadata. Please note that it only works for papers that we have generated summaries for and you can rerun it from time to time to get a more accurate result while our database grows.

Disclaimer: The AI-based summarization tool and virtual assistant provided on this website may not always provide accurate and complete summaries or responses. We encourage you to carefully review and evaluate the generated content to ensure its quality and relevance to your needs.